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Abstract
Objective: Comparing therapeutic effectiveness, safety 
profile, and adherence between Dienogest and postoperative 
Leuprolide Acetate in women with endometriosis who 
underwent laparoscopy.
Methods: This study was a randomized clinical trial 
comparing the open-label study to compare the 
effectiveness of therapy, safety profile, and obedience 
between postoperative dienogest and leuprolide acetate in 
women with endometriosis who underwent laparoscopy. 
Results: From the statistical test it was found that there was 
the effectiveness of dienogest after 4 weeks of therapy (p = 
0.004), after 8 weeks of therapy (p = 0.004) and after 12 weeks 
of therapy (p = 0.004). In the leuprolide acetate group, it was 
also found that there was the effectiveness of administration 
after 4 weeks of therapy (p = 0.004), after 8 weeks of therapy 
(p = 0.004) and after 12 weeks of therapy (p = 0.003). There 
was no difference in systolic blood pressure (p = 0.481), 
diastolic blood pressure (p = 1.000) and pulse frequency 
(p = 0.125) breath frequency (p = 1.000) and temperature 
(p = 0.236) between patients who received dienogest and 
leuprolide acetate. From the statistical analysis, it was found 
that there were no differences in side effects in patients who 
received dienogest and leuprolide acetate (p = 0.238).
Conclusions: There was no difference in therapeutic 
effectiveness, and the safety profile assessed by side effects 
as well as the obedience of postoperative Dienogest and 
Leuprolide Acetate in endometriosis women undergoing 
Laparoscopy because in both groups there was a decrease 
in VAS scores from week to week.
Keywords: endometriosis, dienogest, leuprolide acetate, 
postlaparoscopy, therapy
Abstrak
Tujuan: Membandingkan efektivitas terapi, profil keamanan, 
dan kepatuhan antara dienogest dengan leuprolid asetat 
pascaoperatif pada perempuan endometriosis yang 
menjalani lapararoskopi.
Metode: Penelitian ini merupakan uji klinik acak 
berpembanding dengan studi label terbuka untuk 
membandingkan efektivitas terapi, profil keamanan, 
dan kepatuhan antara dienoges dan leuprolid asetat 
pascaoperatif pada perempuan endometriosis yang 
menjalani lapararoskopi.
Hasil: Dari uji statistik didapatkan hasil terdapat efektivitas 
pemberian dienoges setelah 4 minggu terapi (p = 0,004), 
setelah 8 minggu terapi (p = 0,004), dan setelah 12 minggu 
terapi (p = 0,004). Pada kelompok leuprolid asetat juga 
didapatkan hasil terdapat efektivitas pemberian setelah 
4 minggu terapi (p = 0,004), setelah 8 minggu terapi (p 
= 0,004) dan setelah 12 minggu terapi (p = 0,003).  Tidak 
terdapat perbedaan tekanan darah sistolik (p = 0,481), 
tekanan darahdiastolik (p = 1,000) dan frekuensi nadi (p 
= 0,125) frekuensi napas (p = 1,000) dan suhu (p = 0,236) 
antara pasien yang mendapatkan dienoges dan leuprolid 
asetat. Dari analisis statistik didapatkan hasil tidak terdapat 
perbedaan efek samping pada pasien yang mendapatkan 
dienoges dan leuprolid asetat (p = 0,238).
Kesimpulan: Tidak terdapat perbedaan efektivitas terapi, 
dan profil keamanan yang dinilai dari efek samping serta 
kepatuhan dienoges dan leuprolid asetat pascaoperatif pada 
perempuan endometriosis yang menjalani Lapararoskopi 
karena pada kedua kelompok terdapat penurunan VAS skor 
dari minggu ke minggu.
Kata kunci: endometriosis, dienoges, leuprolide acetate, 
postlaparoscopy, terapi
postlaparoscopic endometriosis and fulfilling the 
study inclusion criteria. The inclusion criteria in this 
study were women of reproductive age who had 
undergone laparoscopy and were diagnosed as 
endometriosis cysts and were classified according 
to revised ASRM criteria with pain complaints 
(VAS> 3) after the first menstruation.  
Exclusion criteria in this study were pregnant, 
lactating or amenorrhoea patients in 3 months 
of screening, patients who had a history of 
endometriosis surgical or medical therapy (such 
as the use of GnRH agonists, danazol progestins, 
and oral contraceptives), experienced liver, 
endocrine, and neoplastic disorders. abnormal 
gynaecological examination and abnormal 
cervical cytology smear. 
Work  Procedures
Identify sufferers including name, age, gender, 
address, diagnosis, education, work and income. 
Special history; obstetric and gynecological 
history (parity, the first day of last menstruation), 
previous history (history of chronic intestinal 
infectious diseases, history of gastrointestinal 
tract surgery, history of chronic kidney disease, 
history of neurological diseases and history 
of chronic liver disease). Physical examination 
included an examination of general conditions, 
blood pressure, pulse, breath, temperature, 
height. Determination of nutritional status 
carried out by measuring pre-treatment weight 
and height, 4th week, 8th week and 12th week 
(measurement of body weight, weighing was 
carried out by researchers assisted by paramedics 
on the subject using the SIMC stand scale plus 
a ZT-120 height gauge, with an accuracy of 100 
grams, height measurement). 
Measurements were made by researchers 
assisted by paramedics, in a standing position 
using the SIMC stand scale plus a ZT-120 height 
gauge. Participants in previous studies are given an 
explanation of the research that will be conducted. 
Those who agreed to participate in this study were 
asked to sign a letter of agreement that had been 
provided for the study. Then for all patients who 
will be included in this study. Determination of 
endometriosis stage is done through diagnostic 
laparoscopy based on endometriosis scoring of 
the American Society of Reproductive Medicine 
(ASRM). This stage is divided into four categories 
of severity. Patients were randomized to a ratio 
of 1: 1 to get oral dienogest at a daily dose of 
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INTRODUCTION
Endometriosis is a gynecological disorder 
characterized by the presence of endometrial like 
tissue located outside the uterus or endometrial 
cavity.1-3 When symptomatic, endometriosis can 
cause chronic pain, dysmenorrhea, dyspareunia, 
non-cyclic pelvic pain, infertility, and bleeding 
disorders.4 The multicentre study reported that 
health care costs related to endometriosis includ-
ed surgery costs (29%), monitoring costs (19%), 
hospital care costs (18%), and doctor consulta-
tion fees (16%). This high cost is related to the 
severity of endometriosis, pelvic pain, infertility, 
and the duration of symptoms before the diag-
nosis.2 Surgical therapy is the best and effective 
approach to eradicate disease and relieve symp-
toms of endometriosis. However, the data show 
a high level of postoperative recurrence and 
complications related to surgical therapy.4-9 The 
use of estrogen-lowering medical therapy after 
short-term surgery is recommended to improve 
the efficacy of therapy, one of which is dienogest. 
Dienogest, has fewer side effects in clinical use, 
has now been used as endometriosis therapy in 
Germany, France and Japan.10 DNG clinical trials 
for 12 and 24 weeks provide information about 
optimum dosages and useful characteristics and 
safety as long-term management of endome-
triosis. Oral 2 mg daily DNG therapy for more 
than 90 weeks caused regression of endometri-
oma and good symptom elimination.11 However, 
comparison of effectiveness, safety profile, and 
obedience of treatment between dienogest and 
Gn-RH analogue, such as leuprolide acetate have 
not been studied much go on. Therefore, further 
research is needed regarding this matter.
METHODS
This study was a randomized clinical trial 
comparing the open-label study to compare 
the effectiveness of therapy, safety profile, and 
obedience between postoperative dienogest and 
leuprolide acetate in women with endometriosis 
who underwent laparoscopy. This research was 
carried out in the Department of Midwifery and 
Gynecology at the RSMH / Faculty of Medicine 
Universitas Sriwijaya, Palembang. The study 
period starts from 01 July 2018 to 28 February 
2019 with the sampling time starting from 01 
July 2018 to 30 November 2018. The study 
sample was women of reproductive age with 
2 mg at the same time every day and injection 
of depot leuprolide acetate (Gn-RH analogue) 
intramuscularly every 4 weeks for 12 weeks (three 
injections). Randomization was carried out during 
postoperative control (7 days postoperatively) 
after definitive histopathological diagnosis of 
endometriosis was available. Dienogest therapy 
is given on the first day after the onset of the 
first postoperative menstrual cycle, whereas 
leuprolide acetate injection begins within the first 
three days of the first postoperative menstrual 
cycle. Both therapies are given for 12 weeks. 
Effectiveness of therapy assessed by assessing 
changes in pain at week 4, week 8, and week 12 
which were assessed through changes in VAS 
assessment.   
Safety profile is a safety profile that is assessed 
based on reports of side effects reported by 
patients and physical examination results (blood 
pressure and weight measurement). These side 
effects were assessed as pre-treatment, week 4, 
week 8, week 12. Obedience is to assess patient 
compliance is undergoing therapy which is 
assessed through a questionnaire (for Dienogest) 
and the accuracy of the date of re-control (for 
Dienogest and Leuprolide acetate).
RESULTS
Randomized clinical trials comparing the open-
label study to compare therapeutic effectiveness, 
safety profile, and obedience between 
postoperative dienogest and leuprolide acetate 
in women with endometriosis who underwent 
laparoscopy have been conducted at the 
Fertility and Endocrinology Clinic Department of 
Obstetrics and Gynecology in RSMH / Medical 
Faculty of UNSRI Palembang. The research 
samples that fulfilled the inclusion and exclusion 
criteria were 20 people, 10 people received 
dienogest and 10 others received leuprolide 
acetate.
General Characteristics of Research Subjects
The general characteristics of the research 
subjects are shown in table 1. Based on age, the 
average age of endometriosis patients was 33.3 
± 6.23 years with an age range of 25-46 years, 
patients aged 20-35 years were 15 people (75%) 
and patients with age> 35 years as many as 5 
people (25%). Both the dienogest and leuprolide 
acetate groups obtained the majority of patients 
aged 20-35 years. The statistical test showed that 
there was no age difference between patients 
who received dienogest and leuprolide acetate 
(p = 1.000). Based on education, it was found that 
the majority of patients had secondary education 
in both the dienogest and leuprolide acetate 
groups. Based on the statistical test, the results 
showed no difference in education between 
patients who received dienogest and leuprolide 
acetate (p = 1.000).
Group P-value*Variable
Table 1. Baseline Data for Research Subjects
Age
20-35  
> 35 
Education
Average
High
Parity
0
1-2
Body Mass Index
Normal
Overweight
Obese
Vas Score
Mean ± SD
Median (Min-Max)
Systolic Blood Pressure
Mean ± SD
Median (Min-Max)
Diastolic Blood Pressure
Mean ± SD
Median (Min-Max)
7 (70.0)
3 (30.0)
6 (60.0)
4 (40.0)
7(70.0)
3 (30.0)
3 (30.0)
3 (30.0)
4 (40.0)
4.90 ± 0.88
5 (4-6)
113.0 ± 4.83
110 (110-120)
71.0 ± 3.16
70 (70-80)
8 (80.0)
2 (20.0)
6 (60.0)
4 (40.0)
9 (90.0)
1 (10.0)
6 (60.0)
1 (10.0)
3 (30.0)
4.60 ± 0.84
4 (4– 6)
113.0 ± 6.75
110 (100– 120)
75.0 ± 5.27
75 (70– 80)
1.000a
1.000a
0.582a
0.343b
0.411c
0.895c
0.057c
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aFisher Exact Test, p = 0.05,  bPearson Chi Square,p =0.05, c Mann-Whitney test, p =0.05
Pulse Frequency
Mean ± SD
Median (Min-Max)
Breath Frequency
Mean ± SD
Median (Min-Max)
Temperature 
Mean ± SD
Median (Min-Max)
82.2 ± 5.99
84 (68-92)
20.8 ± 1.03
20 (20-22)
36.9 ± 0.16
36.8 (36.8-37.3)
82.7 ± 5.21
80 (77– 92)
19.6 ± 1.26
20 (18– 22)
36.7 ± 0.29
36.8 (36.2– 37.2)
0.433c
0.038c
0.137c
The majority of endometriosis patients do 
not have children (80%), both in the dienogest 
and leuprolide acetate groups, the majority of 
patients do not have children. With the statistical 
test, it was found that there was no difference in 
parity between patients who received dienogest 
and leuprolide acetate (p = 0.582). The Body Mass 
Index (BMI) in this study was divided into normal, 
overweight and obese. In the dienogest group, 3 
patients (30%) had normal BMI, 3 patients (30%) 
overweight and 4 patients (40%) obese, while in 
the leuprolide acetate group, 6 patients (60%) 
had normal BMI, 1 patient (10%) overweight and 
3 patients (30%) obese. Based on the statistical 
test, the results showed that there was no 
difference in body mass index between patients 
who received dienogest and leuprolide acetate 
(p = 0.343). This study also found no difference 
in VAS scores (p = 0.411), systolic blood pressure 
(p = 0.895), diastolic blood pressure (p = 0.057), 
pulse frequency (p = 0.433) and temperature (p = 
0.137) between patients who received dienogest 
and leuprolide acetate, but found differences 
in respiratory frequency before intervention 
between patients who received dienogest and 
leuprolide acetate (p = 0.037).
Comparison of the Effectiveness of Dienogest 
and Leuprolide Acetate VAS Score
On figure 1, it can be seen that there is a decrease 
in VAS scores from week to week in both the 
dienogest and leuprolide acetate groups. With 
statistical analysis, it was found that there was 
effectiveness in the administration of dienogest 
after 4 weeks of therapy (p = 0.004), after 8 
weeks of therapy (p = 0.004) and after 12 weeks 
of therapy (p = 0.004). In the leuprolide acetate 
group, it was also found that there was the 
effectiveness of administration after 4 weeks of 
therapy (p = 0.004), after 8 weeks of therapy (p = 
0.004) and after 12 weeks of therapy (p = 0.003). 
Besides, it was found that there was no difference 
in VAS scores after 4 weeks of therapy (p = 0.476), 
after 8 weeks of therapy (p = 0.810) and after 12 
weeks of therapy (p = 1,000) between patients 
who received dienogest and leuprolide acetate. 
Hemodynamic Parameters (Systolic Blood 
Pressure, Diastolic Blood Pressure, Pulse Fre-
quency, Breath Frequency and Temperature)
In this study it was found that there was no 
difference in systolic blood pressure (p = 0.157), 
diastolic blood pressure (p = 0.059) and pulse 
frequency (p = 0.196) dienogest group, but 
differences in respiratory frequency (p = 0.046) 
Tabel 2. Comparison of the effectiveness of therapy in the Dienogest group with Leuprolide Acetate after 4, 8 
and 12 weeks of treatment
Figure 1. Comparison of VAS Score after Therapy
Variable Dienogest
after P-value*before
4.9 ± 0.88
4.9 ± 0.88
4.9 ± 0.88
2.4 ± 1.26
1.0 ± 1.33
0.2 ± 0.42
0.004
0.004
0.004
after P-value* P-value*before
4.6 ± 0.84
4.6 ± 0.84
4.6 ± 0.84
2.7 ± 0.82
0.9 ± 0.74
0.2 ± 0.42
0.004
0.004
0.003
0.476
0.810
1.000
VAS Weeks-4
VAS Weeks-8
VAS Weeks-12
Leuprolid acetat
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and temperature (p = 0.007) in the dienogest 
group, whereas in the leuprolid acetate group it 
was found that there was no difference in diastolic 
blood pressure (p = 0.564) and pulse frequency 
(p = 0.609) breath frequency (p = 0.609) and 
temperature (p = 0.202) but found differences 
systolic blood pressure (p = 0.046). In addition, 
it was found that there was no difference in 
systolic blood pressure (p = 0.481), diastolic 
blood pressure (p = 1.000) and pulse frequency 
(p = 0.125) breath frequency (p = 1,000) and 
temperature (p = 0.236) between patients who 
get dienogest and leuprolide acetate.
Comparison of Safety Profiles Based on 
Amount and Proportion of Side Effects 
Reported Regarding Therapy in Dienogest 
Groups with Leuprolide Acetate
Fourth Week Therapy
No side effects after 4 weeks of therapy were 
found in either patient who received dienogest 
or leuprolide acetate.
Eighth Week Therapy
Side effects found after 8 weeks of therapy in this 
study were 8 out of 20 patients (40%) including 
joint pain, vaginal dryness, headaches and hot 
flushes. Side effects of joint pain and hot flushes 
were found in both groups but side effects of 
vaginal dryness were only found in the leuprolide 
acetate group and headache side effects 
were only found in the dienogest group. With 
statistical analysis, it was found that there were 
no differences in the 8-week side effects between 
patients who received dienogest and leuprolide 
acetate (p = 0.504).
Twelfth Week Therapy
Side effects found after 12 weeks of therapy in this 
study were 14 out of 20 patients (70%) including 
joint pain, vaginal dryness, vaginal dryness with 
decreased libido, headaches, migraines and 
hot flushes. Side effects of vaginal dryness with 
decreased libido and hot flushes were found in 
both groups but side effects of vaginal dryness 
and migraine were only found in the leuprolide 
acetate group and side effects of joint pain and 
headache were only found in the dienogest 
group. With statistical analysis, it was found that 
there were no differences in the 12th-week side 
effects between patients who received dienogest 
and leuprolide acetate (p = 0.238).
Comparison of Compliance Profile between 
Dienogest and Leuprolide Acetate Groups
In the study, endometriosis patients had moderate 
and high adherence to drug consumption. With 
statistical analysis, there was no difference in the 
8th-week compliance (p = 0.211) and 12th (p = 
0.474) between patients who received dienogest 
and leuprolide acetate, only at week 4 there were 
differences in adherence between patients who 
received dienogest and leuprolide acetate (p = 
0.033).
Table 3. Comparison of Compliance Profiles between Dienogest and Leuprolide Acetate Groups
Fisher Exact Test, p =0.05
Variable
4thWeek Compliance, 
HighCompliance
AverageCompliance
8th Week Compliance
High Compliance
Average Compliance
12th Week Compliance
HighCompliance
AverageCompliance
5 (50)
5 (50)
7 (70)
3 (30)
8 (80)
2 (20)
10 (100)
0 (0)
10 (100)
0 (0)
10 (100)
0 (0)
0,033
0,211
0,474
Group P-value*
Dienogest Leuprolide acetate
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DISCUSSION
Endometriosis is a disorder characterized by 
the growth of stromal tissue and ectopic endome-
trial glands (outside the uterus), which can cause 
dysmenorrhoea, dyspareunia, non-cyclic pelvic 
pain, and subfertility.8,12 The peak incidence of en-
dometriosis at the age of 40 years.8Endometriosis 
generally occurs in the reproductive age of 25-
29 years, but can also occur during puberty and 
post-menopausal women who receive hormone 
replacement therapy.13
In this study, the average age of endometriosis 
patients was 33.3 ± 6.23 years with an age range 
of 25-46 years, the majority of endometriosis 
patients in this study were between the ages of 
20-35 years (75%). The results of the study were 
not much different but slightly larger compared 
to the study. In 2014 where the average age of 
endometriosis patients was 31.1 ± 10.4 with a 
range of 17- 53 years. Likewise with the research 
conducted. In 2017 which showed the results of 
the age of endometriosis patients were slightly 
larger compared to this study, which amounted 
to 35.8 ± 4.1 years.
In this study the majority of endometriosis 
patients had secondary education (60%), this 
result is in line with the study. In 2014 which 
received the majority of endometriosis patient 
education was secondary education of 54.3%. 
The majority of endometriosis patients in this 
study did not have children (80%), this is in line 
with the research. In 2017 which showed results 
as much as 42% of endometriosis patients did 
not have children. In 2006 which showed the 
results of the majority of endometriosis patients 
not having children (70.7%).
In addition, a study in 2014 found that as 
many as 62.9% of endometriosis patients did not 
have children. Nuliparitas is closely related to 
endometriosis. The prevalence of endometriosis 
in nulligravida, nulliparous, and with a history of 
abortion was quite high.12
Low body mass index and high consumption 
of caffeine or alcohol increase the risk of endo-
metriosis.14 In this study, 45% of endometriosis 
patients had normal BMI. In line with the results 
of this study, in 2006 it was found that the major-
ity of endometriosis patients had normal BMI. In 
2017 showed a mean BMI of endometriosis pa-
tients of approximately 23.3 kg / m2 where the 
average was in the category of normal BMI.
In this study, the sample was divided into two 
groups, namely the group receiving dienogest 
therapy and one group received leuprolide acetate 
therapy. In addition to age, education, parity and 
body mass index, at the beginning of the study 
VAS examination scores and hemodynamic 
characteristics included systolic blood pressure, 
diastolic, pulse frequency, breathing frequency 
and temperature. Using statistical analysis it was 
found that there were no differences in the initial 
data in both groups, general characteristics, 
hemodynamic characteristics and VAS scores so 
that the two groups were worthy of comparison.
Effectiveness of Dienogest and Leuprolide 
Acetate on score VAS
In this study, the degree of pain was determined 
by using the Visual Analogue Score (VAS), which 
is a 10 cm scale that at the left end is written as 
painless (0) and at the right end is very painful 
(10). The use of VAS scale is easier, more efficient 
and easier for patients to understand compared 
to other scales. VAS also methodologically has 
better quality, where it is also easy to use, only 
uses a few words so the vocabulary does not 
become a problem. William et al also conducted 
a literature review on three pain measuring scales 
and concluded that VAS was statistically the 
strongest because it could present data in form 
ratio. In this study, VAS scores were examined 
before and after administration of dienogest 
therapy and leuprolide acetate therapy.
Dienogest (DNG) is a selective progesterone 
receptor agonist that has been shown to 
reduce endometriosis lesions through several 
biological mechanisms. Dienogest proved to 
be more effective than placebo in reducing 
pain (assessed by visual analogue scale (VAS) 
scores or combinations, such as VAS scores and 
consumption of analgesics (ibuprofen) in women 
with endometriosis with a pelvic pain score of 30 
or more on a scale of 0 -100 (0 = no pain up to 
100 = unbearable pain).8
In this study it was found that there was 
a decrease in VAS scores from week to week 
after administration of dienogest, this showed 
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that dienogest was effective in reducing pain in 
patients with endometriosis after ingestion of 
4, 8 and 12 weeks of therapy. In 2016 showed 
the results of dienogest therapy proved to 
reduce the incidence of dyspareunia (p <0.05), 
dysmenorrhoea (p <0.05), premenstrual pain 
(p <0.05), diffuse pelvic pain or pain during 
examination. Dienogest group 2 mg and 
dienogest 4 mg had less dyspareunia and 
dysmenorrhea (6.9% and 5.7% respectively) than 
pretreatment (51.7% and 57.1%).4
Leuprolide acetate is a synthetic nonapeptide 
GnRH analogue. This drug inhibits synthesis of 
luteinizing hormone (LH) and Follicle Stimulating 
Hormone (FSH) through a negative feedback 
mechanism which further decreases the 
production of estrogen and androgens. Although 
it is not able to effectively eliminate endometrial 
tissue, leuprolide acetate is effective in managing 
symptoms and decreasing the size of the lesion. 
Within 3 months of therapy, leuprolide acetate 
has been proven to be safe and has a positive 
effect to eliminate dysmenorrhoea and pelvic 
pain.
In this study there was a reduction in VAS 
scores from week to week after administration 
of leuprolide acetate, suggesting that leuprolide 
acetate was effective in reducing pain in 
patients with endometriosis after ingestion 
of 4, 8 and 12 weeks of therapy. Clinical trials 
comparing leuprolide acetate and danazol 
800 mg / day concluded that leuprolide has 
the same effectiveness as danazol in reducing 
clinical symptoms and decreasing the size 
of endometriosis lesions. Recent studies and 
clinical trials report that the addition of hormone 
replacement therapy (estradiol/progesterone) 
to patients treated with leuprolide acetate 
minimizes the negative effects of this drug on 
bone and prolongs the pain-free duration1
After comparison, there were no differences 
in VAS scores after 4, 8 or 12 weeks of therapy 
between patients who received dienogest and 
leuprolide acetate. This shows that the dienogest 
is as effective as leuprolide acetate in reducing 
pain in endometriosis patients.
In the hemodynamic characteristics, it was 
found that there was a significant decrease 
in temperature and frequency of breath in 
the group given dienogest but did not show 
a significant difference after being compared 
with the leuprolide acetate group. This shows 
that dienogest and leuprolide have the same 
hemodynamic effects in endometriosis patients.
Increased temperature can reflect an 
increased inflammatory response with pyrogenic 
activity against the phenomenon of retrograde 
menstruation in patients with endometriosis. 
Recent investigations have focused on the 
inflammatory response proportional to 
evaluating serum and Peritoneal Fluid (PF) for 
each component of the response, including 
those related to autoimmunity, peritoneal 
macrophage function, and prostaglandin (PG). It 
is hypothesized that the inflammatory response 
caused by endometriosis results in an increase 
in the number, concentration, and activation of 
the pelvic macrophages. This, in turn, causes the 
release of endogenous pyrogens.
For the safety profile, there is no difference in 
the side effects of using dienogest and leuprolide 
acetate. Side effects that occur include joint pain, 
vaginal dryness, vaginal dryness with decreased 
libido, headaches, migraines and hot flushes. 
Side effects of vaginal dryness with decreased 
libido and hot flushes were found in both groups 
but side effects of vaginal dryness and migraine 
were only found in the leuprolide acetate group 
and side effects of joint pain and headache were 
only found in the dienogest group.
In this study, we can conclude that there is 
no difference in therapeutic effectiveness, safety 
profile, and obedience between Dienogest 
and postoperative Leuprolide Acetate in 
endometriosis women undergoing Laparoscopy, 
which means the null hypothesis is accepted.
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